HIV/AIDS

Vaccines

More than 30 million people worldwide live with HIV (UNAIDS 2008). Currently, there is no vaccine available to prevent HIV infection. Anti-retroviral therapy can control progression to AIDS but cannot cure or thwart spread of the disease, and for every individual that begins treatment about 3 more become infected. Historically, vaccines have significantly impacted the spread of infectious diseases such as smallpox, polio, measles, and yellow fever. Similarly, HIV vaccines represent the best long-term hope for ending the HIV pandemic, and HIV vaccine research is a top priority for NIAID.

Special Announcements

• New RFAs issued:
• B Cell Immunology Partnership Program For HIV-1 Vaccine Discovery
• Dissecting the Early HIV Immune Response: A Systems Biology Approach
• Two RFAs reissued
• Basic HIV Vaccine Discovery Research
• Highly Innovative Tactics to Interrupt Transmission of HIV
• NIAID ARRA Funds to Accelerate High-Quality Research
• Acute HIV infection Workshop on September 22-23, 2009 at Boston, MA
• Application of B-cell Biology Principles to HIV Vaccine Research

Latest News

From Our Partners

• Center for HIV/AIDS Vaccine Immunology (CHAVI) 2008: Forging New Way Ahead
• HIV Vaccine Trials Network (HVTN) 2008: Reshaped scientific agenda involves understanding the clinical and immunological aspects of the Step trial

From Recent Meetings

• Keystone Symposia 2009 - New Discoveries Provide Insight into Protective Immune Responses to HIV
• AIDS Vaccine 2008 - New Discoveries Energize the HIV Vaccine Field

back to top